Diagnose und Therapie der heparininduzierten Thrombozytopenie

Schlüsselwörter

Heparin - Thrombozytopenie - Thromboembolie - Antikoagulation - Thrombininhibitoren

Keywords

heparin - thrombozytopenia - thromboembolism - anticoagulation - thrombin inhibitors

Literatur

• 1 Arepally G M, Ortel T L. Clinical practice. Heparin-induced thrombocytopenia.  N Engl J Med. 2006;  355 809-817
• 2 Begelman S M, Baghdasarian S B, Singh I M. et al . Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.  J Intensive Care Med. 2008;  23 313-320
• 3 Beiderlinden M, Treschan T A, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients.  Ann Pharmacother. 2007;  41 749-754
• 4 Cochran K, DeMartini T J, Lewis B E. et al . Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.  J Invasive Cardiol. 2003;  15 617-621
• 5 Efird L E, Kockler D R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.  Ann Pharmacother. 2006;  40 1383-1387
• 6 Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.  Blood. 2000;  96 2373-2378
• 7 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
• 8 Fischer K G. Hirudin in renal insufficiency.  Semin Thromb Hemost. 2002;  28 467-482
• 9 Greinacher A. Heparin-induced thrombocytopenia.  J Thromb Haemost. 2009;  7 Suppl 1 9-12
• 10 Greinacher A, Althaus K, Krauel K, Selleng S. Heparin-induced thrombocytopenia.  Hamostaseologie. 2010;  30 17-18
• 11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 12 Greinacher A, Farner B, Kroll H. et al . Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.  Thromb Haemost. 2005;  94 132-135
• 13 Greinacher A, Juhl D, Strobel U. et al . Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.  J Thromb Haemost. 2007;  5 1666-1673
• 14 Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.  Chest. 2005;  127 1S-8S
• 15 Hursting M J, Verme-Gibboney C N. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.  J Cardiovasc Pharmacol. 2008;  52 561-566
• 16 Keegan S P, Ernst N E, Mueller E W. Argatroban for anticoagulation in continuous renal replacement therapy.  Crit Care Med. 2009;  37 2139; author reply 2139-2140
• 17 Kern H, Ziemer S, Kox W J. Bleeding after intermittent or continuous r-hirudin during CVVH.  Intensive Care Med. 1999;  25 1311-1314
• 18 Kiser T H, Burch J C, Klem P M, Hassell K L. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.  Pharmacotherapy. 2008;  28 1115-1124
• 19 Kiser T H, Fish D N. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.  Pharmacotherapy. 2006;  26 452-460
• 20 Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial.  J Thorac Cardiovasc Surg. 2006;  132 699-700
• 21 Krauel K, Pötschke C, Weber C. et al . Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia.  Blood. 2011;  117 (4) 1370-1378
• 22 Lewis B E, Matthai Jr W H, Cohen M. et al . Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
• 23 Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.  Clin Appl Thromb Hemost. 2001;  7 300-304
• 24 Lindhoff-Last E, Piechottka G P, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level.  Thromb Res. 2000;  100 55-60
• 25 Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy.  Crit Care Med. 2009;  37 105-110
• 26 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
• 27 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104 3072-3077
• 28 Lubenow N, Eichler P, Lietz T. et al . Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospecive study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.  J Thromb Haemost. 2005;  3 2428-36
• 29 Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.  BioDrugs. 2000;  14 109-125
• 30 Lubenow N, Hinz P, Thomaschewski S. et al . The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.  Blood. 2010;  115 1797-1803
• 31 Magnani H N. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis.  Thromb Res. 2010;  125 e171-e176
• 32 Magnani H N, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.  Thromb Haemost. 2006;  95 967-981
• 33 Mahaffey K W, Lewis B E, Wildermann N M. et al . The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.  J Invasive Cardiol. 2003;  15 611-616
• 34 Martel N, Lee J, Wells P S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.  Blood. 2005;  106 2710-2715
• 35 Murray P T, Reddy B V, Grossman E J. et al . A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.  Kidney Int. 2004;  66 2446-2453
• 36 Oliveira G B, Crespo E M, Becker R C. et al . Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.  Arch Intern Med. 2008;  168 94-102
• 37 Polkinghorne K R, McMahon L P, Becker G J. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.  Am J Kidney Dis. 2002;  40 990-995
• 38 Rauova L, Zhai L, Kowalska M A. et al . Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.  Blood. 2006;  107 2346-2353
• 39 Reddy B V, Grossman E J, Trevino S A, Hursting M J, Murray P T. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.  Ann Pharmacother. 2005;  39 1601-1605
• 40 Selleng S, Malowsky B, Itterman T. et al . Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.  Am Heart J. 2010;  160 362-369
• 41 Vargas Hein O, Kox W J, Spies C. Anticoagulation in continuous renal replacement therapy.  Contrib Nephrol. 2004;  144 308-316
• 42 Vargas Hein O, von Heymann C, Lipps M. et al . Hirudin versus heparin for anticoagulation in continuous renal replacement therapy.  Intensive Care Med. 2001;  27 673-679
• 43 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
• 44 Warkentin T E, Greinacher A, Koster A, Lincoff A M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 340S-380S
• 45 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 46 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis.  Ann Intern Med. 2001;  135 502-506
• 47 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344 1286-1292
• 48 Warkentin T E, Maurer B T, Aster R H. Heparin-induced thrombocytopenia associated with fondaparinux.  N Engl J Med. 2007;  356 2653-2655
• 49 Selleng K, Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia in intensiv care patients.  Crit Care Med. 2007;  35 1165-1176